A genetic risk score is associated with statin-induced low-density lipoprotein cholesterol lowering. (April 2016)

• Record Type: Journal Article
• Authors: Leusink, Maarten; Maitland-van der Zee, Anke H; Ding, Bo; Drenos, Fotios; van Iperen, Erik PA; Warren, Helen R; Caulfield, Mark J; Cupples, L Adrienne; Cushman, Mary; Hingorani, Aroon D; Hoogeveen, Ron C; Hovingh, G Kees; Kumari, Meena; Lange, Leslie A; Munroe, Patricia B; Nyberg, Fredrik; Schreiner, Pamela J; Sivapalaratnam, Suthesh; de Bakker, Paul IW; de Boer, Anthonius; Keating, Brendan J; Asselbergs, Folkert W; Onland-Moret, N Charlotte
• Is Part Of: Pharmacogenomics. Volume 17:Number 6(2016)
• Page Start: 583
• Page End: 591
• Publication Date: 2016-04
• Subjects: pharmacogenetics cholesterol -- risk score -- statin therapy; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs.16.8
• Languages: English
• ISSNs: 1462-2416

Abstract

Aim: To find new genetic loci associated with statin response, and to investigate the association of a genetic risk score (GRS) with this outcome.Patients & methods: In a discovery meta-analysis (five studies, 1991 individuals), we investigated the effects of approximately 50000 single nucleotide polymorphisms on statin response, following up associations with p < 1 × 10 -4 (three independent studies, 5314 individuals). We further assessed the effect of a GRS based on SNPs in ABCG2, LPA and APOE .Results: No new SNPs were found associated with statin response. The GRS was associated with reduced statin response: 0.0394 mmol/l per allele (95% CI: 0.0171–0.0617, p = 5.37 × 10 -4 ).Conclusion: The GRS was associated with statin response, but the small effect size (˜2% of the average low-density lipoprotein cholesterol reduction) limits applicability.